Fig. 4

Targeting TMEM17 suppressed CSC characteristic in CRC cells. a Genic depleting TMEM17 reduced cancer cell sphere formation, n = 3. The bar = 400um. b Tumorsphere formation assay of CRC cells with depleting TMEM17 and 5-Fu treatment, n = 3. c Tumorsphere formation assay of CRC cells with depleting TMEM17 and Oxaliplation treatment, n = 3. d Immunoblotting assay of the expression of TMEM17, EPCAM and LGR5 proteins from CRC cells with scramble or TMEM siRNA. (Left) Immunoblotting assay of the expression of TMEM17, EPCAM and LGR5 proteins from CRC cells with vector or TMEM17. (Right) e Immunoblotting assay of the expression of TMEM17, EPCAM and LGR5 proteins from CRC cells with adherent culture or tumorsphere culture. f Clonogenic assay of DLD1 and DLD1 oxaliplatin resistance cells. g Immunoblotting assay of DLD1 and DLD1 oxaliplatin resistance cells. Error bars represent ± SD. **P < 0.01, *P < 0.05, paired sample T test (a–c)